Five state legislatures now allow terminal patients to circumvent the FDA. Will this new path to experimental drugs help or hurt?
Trials that involve new drugs being compared to existing versions could let inferior treatments slip through.
When controversy erupts over the safety of a drug, chances are, Steven E. Nissen is not far away.
Issues of choice, good science and the benefit of new treatments complicate the question.
No Articles Found.